206.16
2.64 (1.30%)
| Penutupan Terdahulu | 203.52 |
| Buka | 204.52 |
| Jumlah Dagangan | 273,488 |
| Purata Dagangan (3B) | 201,659 |
| Modal Pasaran | 4,057,583,360 |
| Harga / Pendapatan (P/E TTM) | 90.82 |
| Harga / Pendapatan (P/E Ke hadapan) | 24.88 |
| Harga / Jualan (P/S) | 14.97 |
| Harga / Buku (P/B) | 4.00 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Keuntungan | -73.07% |
| Margin Operasi (TTM) | -80.87% |
| EPS Cair (TTM) | -7.29 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 46.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.56% |
| Nisbah Semasa (MRQ) | 5.27 |
| Aliran Tunai Operasi (OCF TTM) | 52.87 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 63.35 M |
| Pulangan Atas Aset (ROA TTM) | -1.14% |
| Pulangan Atas Ekuiti (ROE TTM) | -16.56% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Ligand Pharmaceuticals Incorpor | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 0.5 |
| Purata | 0.00 |
|
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.35% |
| % Dimiliki oleh Institusi | 100.00% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 250.00 (Oppenheimer, 21.27%) | Beli |
| Median | 232.50 (12.78%) | |
| Rendah | 220.00 (Benchmark, 6.71%) | Beli |
| Purata | 233.75 (13.38%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 202.81 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| RBC Capital | 10 Nov 2025 | 234.00 (13.50%) | Beli | 209.29 |
| Benchmark | 07 Nov 2025 | 220.00 (6.71%) | Beli | 202.48 |
| HC Wainwright & Co. | 06 Nov 2025 | 231.00 (12.05%) | Beli | 208.22 |
| Oppenheimer | 03 Nov 2025 | 250.00 (21.27%) | Beli | 191.24 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| KOZARICH JOHN W | - | 196.29 | -467 | -91,667 |
| Jumlah Keseluruhan Kuantiti Bersih | -467 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -91,667 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 196.29 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| KOZARICH JOHN W | Pengarah | 01 Dec 2025 | Jual automatik (-) | 467 | 196.29 | 91,667 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 06 Nov 2025 | Pengumuman | Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance |
| 30 Oct 2025 | Pengumuman | Ligand to Participate in November Investor Conferences |
| 23 Oct 2025 | Pengumuman | Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025 |
| 16 Oct 2025 | Pengumuman | Ligand to Host Investor Day on December 9, 2025 |
| 09 Oct 2025 | Pengumuman | Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |